It’s out! Thrilled to share our expanded genome-wide association study 🧬 of preeclampsia + gestational hypertension 🤰 in @NatureMedicine. 🙏 to the reviewers/editors who improved this paper from the preprint. Paper here: Short thread.👇. (1/8)

RT @pnatarajanmd: Building on the legacy of many, I'm incredibly excited that we have successfully translated our polygenic risk scores int….

Join millions who have switched to Grok.

Low-Dose Colchicine May Slow Growth of Clonal Hematopoiesis - American College of Cardiology @NiekMohamma

RT @Bweber04: SOO proud of rockstar 🔥💥@chrispan05 for receiving the YIA award in prevention cardiology @escardio on Psoriasis metabolomics!….

RT @JGrapsa: Wonderful exchange of science and terrific lectures by @mchonig @MassGenBrigham and @Borjaibanez1 @CNIC_CARDIO at the 8th MGB….

So proud of these 3 for their simultaneous pubs with #ESCCongress2025 @escardio . @daniel_ezt @JACCJournals (.@NiekMohamma @JACCJournals (.@artschuermans @JAMACardio (

RT @pnatarajanmd: Major congrats to @mchonig with THREE simultaneous senior-author publications during #ESCCongress25 each with a different….

RT @artschuermans: Does clonal hematopoiesis of indeterminate potential (CHIP) predict heart inflammation?. Thrilled to share our work iden….

RT @nathalie_conrad: Brilliant study led by @artschuermans and @mchonig ! #ESCCongress2025.

RT @EricTopol: New report that CHIP (clonal hematopoiesis of indeterminate potential, blood stem cell clones that increase with age) is an….

RT @JAMACardio: Among middle-aged adults, clonal hematopoiesis of indeterminate potential (CHIP) was linked to an increased risk of develop….

RT @yash_pershad: Longitudinal analysis of the LoDoCo2 clinical trial suggests that colchicine blunts TET2 CHIP expansion possibly mediated….

RT @ACCinTouch: 📺 ACC Anywhere TV From ESC Congress 2025 Quick Take: Dr. @mchonig discusses clonal hematopoiesis of indeterminate potential….

RT @ACCinTouch: @JACCJournals #JACC #ESCCongress.

RT @KelvinS_MD: A superstar in the making @daniel_ezt ✨mentored by the amazing @mchonig! . A very important finding showing that specific s….

RT @MitsuakiSawano: 🆕 I had the pleasure of interviewing Dr. Michael Honigberg (@mchonig ), corresponding author of two simultaneous @JACCJ….

@daniel_ezt (6/X). Super proud of Nieky for his outstanding LBCT presentation at #ESC2025 . 🙏🙏 to coauthors incl @M_Mesbah_Uddin @NakaoTetsushi @pnatarajanmd and the entire LoDoCO2 team who were amazing collaborators. OA paper here:

@daniel_ezt (5/X). In addition, colchicine therapy significantly blunted a rise in IL-6 levels in individuals with non-DNMT3A CH. Overall, these findings suggest the potential for colchicine to slow the growth of key CH driver mutations & mitigate their associated risk of CVD

@daniel_ezt (4/X). Randomization to colchicine vs. placebo led to attenuated grown in CH driven by mutations other than DNMT3A. with statistically significant reduction in growth for TET2 CH. (TET2 is the 'common' CH driver most consistently linked to CVD)

@daniel_ezt (3/X). LoDoCo2 tested colchicine 0.5 mg daily in 5,522 Dutch & Australian individuals w/ chronic CAD and found a 31% MACE ⬇️. In this substudy, we performed deep targeted 🧬sequencing 2,047 samples across 4 timepoints from 854 Dutch LoDoCo2 participants to detect & quantify CH

(2/X). As demonstrated in @daniel_ezt ‘s paper ( also presented today at #ESC2025, key subtypes of CH, e.g., clones driven by mutations in TET2, are a risk factor for CVD. Larger clones associate w/ ⬆️ CVD risk.